Phase 3 Clinical Trials With Primary Completion Dates in February 2017

This is a list of Phase 3 trials with primary completion dates in February 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AERI Aerie Pharmaceuticals, Inc. 2017-02-01 Phase 3 NCT02674854 Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
ANTH Anthera Pharmaceuticals, Inc. 2017-02-01 Phase 3 NCT02279498 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis
CEMP Cempra, Inc. 2017-02-01 Phase 3 NCT02570490 Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
EARS Auris Medical Holding AG 2017-02-01 Phase 3 NCT01934010 AM-101 in the Treatment of Post-Acute Tinnitus 1
FGEN FibroGen, Inc 2017-02-01 Phase 3 NCT02174731 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis
IPXL Impax Laboratories, Inc. 2017-02-01 Phase 3 NCT02770365 Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy
MYGN Myriad Genetics, Inc. 2017-02-01 Phase 3 NCT01844986 Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NKTR Nektar Therapeutics 2017-02-01 Phase 3 NCT02362672 Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain
REPH Recro Pharma, Inc. 2017-02-01 Phase 3 NCT02720692 Evaluation of N1539 Following Major Surgery
TRVN Trevena, Inc. 2017-02-01 Phase 3 NCT02820324 Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
TRVN Trevena, Inc. 2017-02-01 Phase 3 NCT02815709 Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
TRVN Trevena, Inc. 2017-02-01 Phase 3 NCT02656875 A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain
ZGNX Zogenix, Inc. 2017-02-01 Phase 3 NCT02682927 A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome